These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 12506681

  • 21. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children.
    Madrazo-de la Garza A, Dibildox M, Vargas A, Delgado J, Gonzalez J, Yañez P.
    J Pediatr Gastroenterol Nutr; 2003 Feb; 36(2):261-5. PubMed ID: 12548064
    [Abstract] [Full Text] [Related]

  • 22. [Electrochemical behaviour of pantoprazole].
    Knoth H.
    Pharmazie; 2004 Mar; 59(3):231. PubMed ID: 15074600
    [Abstract] [Full Text] [Related]

  • 23. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.
    Corinaldesi R, Valentini M, Belaïche J, Colin R, Geldof H, Maier C.
    Aliment Pharmacol Ther; 1995 Dec; 9(6):667-71. PubMed ID: 8824655
    [Abstract] [Full Text] [Related]

  • 24. Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome.
    Désir B, Poitras P.
    Can J Gastroenterol; 2001 Dec; 15(12):795-8. PubMed ID: 11773945
    [Abstract] [Full Text] [Related]

  • 25. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD, Ducrotté P, Vallot T.
    Presse Med; 2004 Jun 19; 33(11):746-54. PubMed ID: 15257232
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K, Lind T, Wilder-Smith C.
    Eur J Clin Pharmacol; 2004 Oct 19; 60(8):531-9. PubMed ID: 15349707
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions.
    Kaplan GG, Bates D, McDonald D, Panaccione R, Romagnuolo J.
    Clin Gastroenterol Hepatol; 2005 Dec 19; 3(12):1207-14. PubMed ID: 16361046
    [Abstract] [Full Text] [Related]

  • 31. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
    Frazzoni M, De Micheli E, Grisendi A, Savarino V.
    Aliment Pharmacol Ther; 2003 Jan 19; 17(2):235-41. PubMed ID: 12534408
    [Abstract] [Full Text] [Related]

  • 32. Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: a multicentre comparative study.
    Andrews CN, Levy A, Fishman M, Hahn M, Atkinson K, Kwan P, Enns R.
    Can J Gastroenterol; 2005 Nov 19; 19(11):667-71. PubMed ID: 16292361
    [Abstract] [Full Text] [Related]

  • 33. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.
    Luo JY, Niu CY, Wang XQ, Zhu YL, Gong J.
    World J Gastroenterol; 2003 Nov 19; 9(11):2583-6. PubMed ID: 14606102
    [Abstract] [Full Text] [Related]

  • 34. A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.
    van Hout BA, Klok RM, Brouwers JR, Postma MJ.
    Clin Ther; 2003 Feb 19; 25(2):635-46. PubMed ID: 12749518
    [Abstract] [Full Text] [Related]

  • 35. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
    Hartmann M, Theiss U, Huber R, Lühmann R, Bliesath H, Wurst W, Lücker PW.
    Aliment Pharmacol Ther; 1996 Jun 19; 10(3):359-66. PubMed ID: 8791964
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP, Campoli-Richards DM.
    Drugs; 1986 Jul 19; 32(1):15-47. PubMed ID: 3527658
    [Abstract] [Full Text] [Related]

  • 38. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.
    Kromer W, Krüger U, Huber R, Hartmann M, Steinijans VW.
    Pharmacology; 1998 Feb 19; 56(2):57-70. PubMed ID: 9494064
    [Abstract] [Full Text] [Related]

  • 39. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
    Metz DC, Soffer E, Forsmark CE, Cryer B, Chey W, Bochenek W, Pisegna JR.
    Am J Gastroenterol; 2003 Feb 19; 98(2):301-7. PubMed ID: 12591045
    [Abstract] [Full Text] [Related]

  • 40. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
    Giannini E, Romagnoli P, Fasoli A, Chiarbonello B, Malfatti F, Botta F, Risso D, Lantieri PB, Savarino V, Testa R.
    Am J Gastroenterol; 2000 Oct 19; 95(10):2762-7. PubMed ID: 11051345
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.